Theragnostics Ltd
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma (NCT06650605) | Theragnostics Ltd | 2024-07-04 |
| 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer (NCT03617588) | Theragnostics Ltd | 2018-06-18 |
Track Theragnostics Ltd automatically
Every clearance here is in the API, with alerts when new ones post.